Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Italo Linfante

Neuroradiology Miami, FL Medical Doctor

NPI 1073549705 CMS profile 3019

8950 N Kendall Dr Ste 407W, Miami, FL 33176

Open in the dashboard

General payments

$274,580

296 records reported · program years 2019–2025

Research payments

$33,125

Paid to them · 15 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$6,570 paid to institutions, not to them · program years 2019–2021

Through program year 2025, Italo Linfante of Miami, FL is reported in the CMS Open Payments database as having received $274,580 across 296 general payments and $33,125 in research payments paid to them. Separately, studies naming them as principal investigator received $6,570 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 97th percentile of Neuroradiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

11 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $57,070 55
2025 Research $10,200 4
2024 General $78,801 71
2024 Research $9,975 5
2023 General $15,492 23
2023 Research $9,100 4
2022 General $43,168 43
2022 Research $3,850 2
2021 General $4,934 34
2020 General $13,389 18
2019 General $61,725 52

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Italo Linfante
  • Neuroradiology median
  • Middle half of Neuroradiology
  • National median

In program year 2025, general payments to Italo Linfante were reported at $57,070. Among 399 Neuroradiology profiles paid that year, the median was $279 and the middle half received between $65 and $2,205.

Show as a table
Year Italo Linfante Neuroradiology median Middle half National median
2019 $61,725 $288 $71–$2,035 $163
2020 $13,389 $165 $32–$1,794 $114
2021 $4,934 $238 $42–$1,807 $132
2022 $43,168 $191 $49–$1,388 $149
2023 $15,492 $228 $56–$1,148 $160
2024 $78,801 $241 $97–$2,192 $164
2025 $57,070 $279 $65–$2,205 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Stryker Corporation $128,820 112 payments
  2. Medtronic USA, Inc. $46,188 31 payments
  3. Medtronic, Inc. $29,976 25 payments
  4. Penumbra, Inc. $24,151 21 payments
  5. Medical Device Business Services, Inc. $13,342 5 payments
  6. Qapel Medical Inc $9,245 1 payment
  7. Philips Electronics North America Corporation $5,489 6 payments
  8. DePuy Synthes Products, Inc. $5,350 3 payments
  9. Chiesi USA, Inc. $3,875 1 payment
  10. Viz.Ai, Inc. $2,243 5 payments
  11. Other $5,901 86 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $153,557 33 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $70,920 26 payments
  3. Travel and Lodging $40,936 74 payments
  4. Food and Beverage $9,166 163 payments
Products named General payments · program years 2019–2025
  1. SURPASS EVOLVE $55,313 52 payments
  2. Pipeline Flow Diversion $27,663 21 payments
  3. Penumbra System $21,356 9 payments
  4. TARGET $20,098 6 payments
  5. AXS VECTA 71 $19,429 4 payments
  6. INFINITY $16,293 2 payments
  7. NEUROFORM EZ 3 $14,248 4 payments
  8. FLOWGATE $13,579 3 payments
  9. Pipeline Flow Diversion $12,823 21 payments
  10. CORE $12,760 5 payments
  11. Other $97,177 187 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Medtronic, Inc. $26,100 11 payments
  2. Balt USA, LLC $7,025 4 payments

Billing to Medicare

Part B · data year 2024 · 31 billing codes

Paid by Medicare

$116,680

Medicare's payments for the services billed

Medicare patients

136

Average age 77

Services billed

574

78 women, 58 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 54%
Ischemic heart disease 49%
Diabetes 35%
Atrial fibrillation 31%
Chronic kidney disease 31%
Depression 31%
COPD 28%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

311 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neuroradiology in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record